142 related articles for article (PubMed ID: 17594597)
41. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis.
Galland F; Lacroix L; Saulnier P; Dessen P; Meduri G; Bernier M; Gaillard S; Guibourdenche J; Fournier T; Evain-Brion D; Bidart JM; Chanson P
Endocr Relat Cancer; 2010 Jun; 17(2):361-71. PubMed ID: 20228124
[TBL] [Abstract][Full Text] [Related]
42. Clinicopathological analysis of nonfunctioning pituitary adenomas in patients younger than 25 years of age.
Yamaguchi-Okada M; Inoshita N; Nishioka H; Fukuhara N; Yamada S
J Neurosurg Pediatr; 2012 May; 9(5):511-6. PubMed ID: 22546029
[TBL] [Abstract][Full Text] [Related]
43. Gender-related differences in non-functioning pituitary adenomas.
Schaller B
Neuro Endocrinol Lett; 2003 Dec; 24(6):425-30. PubMed ID: 15073569
[TBL] [Abstract][Full Text] [Related]
44. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
45. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
47. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
[TBL] [Abstract][Full Text] [Related]
48. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
49. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients.
Mastronardi L; Guiducci A; Puzzilli F; Maira G
Clin Neurol Neurosurg; 2002 Jan; 104(1):44-8. PubMed ID: 11792476
[TBL] [Abstract][Full Text] [Related]
50. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
51. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
52. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
Widhalm G; Wolfsberger S; Preusser M; Fischer I; Woehrer A; Wunderer J; Hainfellner JA; Knosp E
J Neurosurg; 2009 Sep; 111(3):563-71. PubMed ID: 18991501
[TBL] [Abstract][Full Text] [Related]
53. Recurrence in pituitary adenomas in childhood and adolescence.
Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
[TBL] [Abstract][Full Text] [Related]
54. Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1.
Abe T; Sanno N; Osamura YR; Matsumoto K
Acta Neurochir (Wien); 1997; 139(7):613-8. PubMed ID: 9265953
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
[TBL] [Abstract][Full Text] [Related]
56. Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior.
Pegolo G; Buckwalter JG; Weiss MH; Hinton DR
Acta Cytol; 1995; 39(5):887-92. PubMed ID: 7571965
[TBL] [Abstract][Full Text] [Related]
57. Expression of proliferation markers in human pituitary incidentalomas.
Suzuki M; Minematsu T; Oyama K; Tahara S; Miyai S; Sanno N; Osamura RY; Teramoto A
Endocr Pathol; 2006; 17(3):263-75. PubMed ID: 17308363
[TBL] [Abstract][Full Text] [Related]
58. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.
Ekramullah SM; Saitoh Y; Arita N; Ohnishi T; Hayakawa T
Acta Neurochir (Wien); 1996; 138(12):1449-55. PubMed ID: 9030353
[TBL] [Abstract][Full Text] [Related]
59. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
60. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
